Forward-Looking Statements

Materials on this website may contain information about the future plans and prospects of Advantx Pharmaceuticals Inc. and its representatives that constitute forward-looking statements for the purposes of the safe harbor provisions under the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,”, “promising”,  “potential”, “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters.

Advantx Pharmaceuticals Inc does not have any approved drugs and cannot guarantee that the therapeutic candidates it is developing will reach the market. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in the commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not put undue reliance on these statements or the scientific data presented.

Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Advantx Pharmaceuticals Inc. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Advantx Pharmaceuticals Inc. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Advantx Pharmaceuticals Inc. will obtain regulatory approval for any “phase” of clinical trials. Advantx Pharmaceuticals Inc. does not currently have any approved drugs and cannot be sure of the clinical outcome for efficacy or safety of our candidates.

In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events, or otherwise. Consequently, Advantx Pharmaceuticals Inc. will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.